


PATENT

Docket No. 28967/34140A

**UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

In the Application of: Alitalo, et al.	)	I hereby certify that this paper is being
	)	deposited with the United States Postal
Serial No.: 09/534,376	)	Service with sufficient postage as first
	)	class mail in an envelope addressed to:
Filed: March 24, 2000	)	Commissioner for Patents
	)	Washington, D.C. 20231
For: VASCULAR ENDOTHELIAL	)	
GROWTH FACTOR C (VEGF-C)	)	
PROTEIN AND GENE,	)	
MUTANTS THEREOF, AND	)	September 21, 2001
USES THEREOF	)	
	)	
Group Art Unit: 1646	)	
	)	
Examiner: E. O'Hara	)	David A. Gass
	)	Registration No. 38,153
	)	Attorney for Applicants

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98**Commissioner for Patents  
Washington, D.C. 20231

Ladies and Gentlemen:

In compliance with 37 C.F.R. §1.97 and the duty of disclosure under 37 C.F.R. §1.56, the Applicants request that the documents listed on the attached form PTO-1449 be considered and made of record in the above-identified patent application. Copies of all of the cited documents are enclosed herewith.

The Patent Office will observe that many of the cited PCT documents allege priority in U.S. patent applications filed before the PCT application. The Patent Office, of course, should have any such relevant applications at its disposal.

Documents B12-B15, C1, C24, C102-C106 and C116-C117 were cited in foreign search reports of related applications.

This Information Disclosure Statement is submitted before the mailing of a first Office action on the merits, and consequently should be considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However, please charge any required fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

September 21, 2001

By:



David A. Gass

Registration No.: 38,153

Form PTO 1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34140ASerial No.  
09/534,376

## INFORMATION DISCLOSURE STATEMENT

Applicant  
Alitalo *et al.*Filing Date  
March 24, 2000Group  
1632

(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
EA	B1	WO 91/09955	07/11/91	WIPO				
EA	B2	O 506 477 A1	03/27/92	EP				
EA	B3	WO 92/20808	11/26/92	WIPO				
EA	B4	WO 94/12650	06/09/94	WIPO				
EA	B5	WO 95/24473	09/14/95	WIPO				
EA	B6	WO 95/33050	12/07/95	WIPO				
EA	B7	WO 95/33772	12/14/95	WIPO				
EA	B8	WO 96/11269	04/18/96	WIPO				
EA	B9	WO 96/30046	10/03/96	WIPO				
EA	B10	WO 96/39421	12/12/96	WIPO				
EA	B11	WO 96/39515	12/12/96	WIPO				
EA	B12	WO 97/05250 A	02/13/97	WIPO				
EA	B13	WO 97/09427 A	03/13/97	WIPO				
EA	B14	WO 97/17442 A	05/15/97	WIPO				
EA	B15	WO 95/26364	10/05/95	WIPO			English- language Abstract Only	
EA	B16	WO 98/02543	07/15/97	WIPO			English Abstract only	
	B17	WO 98/49300	06/13/97	WIPO				
EA	B18	WO 99/46364	09-16-99	WIPO				
EA	B19	WO 00/21560	04-20-00	WIPO				

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)  <b>INFORMATION DISCLOSURE STATEMENT</b>  <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office	Apty. Docket No. <b>28967/34140A</b>	Serial No. <b>09/534,376</b>
		Applicant <b>Alitalo <i>et al.</i></b>	
		Filing Date <b>March 24, 2000</b>	Group <b>1632</b>

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
EA	B20	WO 00/24412	05-04-00	WIPO				
EA	B21	WO 00/58511	10-05-00	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
EA	C1	Achen, M.G. <i>et al.</i> , "Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4)," <i>Proceedings of the National Academy of Science, USA</i> , 95:548-553 (January, 1998).
EA	C2	Adams, M.D. <i>et al.</i> , "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence," <i>Nature</i> , 377(6547 Supplement):3-174 (September, 1995).
EA	C3	Alitalo <i>et al.</i> , "Vascular Endothelial Growth Factors and Receptors Involved in Angiogenesis," <i>The 9th International Conference of the International Society of Differentiation (ISD), Development, Cell Differentiation and Cancer</i> , Pisa (Italy), September 28-October 2, 1996, p. 66 (ABSTRACT S22).
EA	C4	Alitalo <i>et al.</i> , "Vascular Endothelial Growth Factors B and C and Receptors Involved in Angiogenesis," <i>German-American Academic Council Foundation (GAAC)/ Stiftung Deutsch-Amerikanisches Akademisches Konzil (DAAK), 2nd Symposium on Current Problems in Molecular Medicine: The Role of Cytokines in Human Disease</i> , November 17-20, 1996, Ringberg Castle, Germany, p. 1 (ABSTRACT).
EA	C5	Andersson <i>et al.</i> , "Assignment of Interchain Disulfide Bonds in Platelet-Derived Growth Factor (PDGF) and Evidence for Agonist Activity of Monomeric PDGF," <i>J. Biol. Chem.</i> , 267(16):11260-11266 (June 5, 1992).
EA	C6	Aprelikova <i>et al.</i> , "FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," <i>Cancer Research</i> , 52:746-748 (February 1, 1992).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

App. Docket No.

28967/34140A

Serial No.

09/534,376

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

EA	C7	Asahara <i>et al.</i> , Isolation of Putative Progenitor Endothelial Cells for Angiogenesis," <i>Science</i> , 275: 964-967 (February, 1997).
EA	C8	Auffray <i>et al.</i> H. sapiens partial cDNA sequence; clone c-1wf11. EST-STS Accession No. Z44272. 11/06/94
EA	C9	Ausprunk, <i>et al.</i> , "Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels during Tumor Angiogenesis," <i>Microvasc. Res.</i> , 14:53-65 (1977).
EA	C10	Basilico <i>et al.</i> , "The FGF Family of Growth Factors and Oncogenes," <i>Adv. Cancer Res.</i> , 59:145-165 (1992).
EA	C11	Berse <i>et al.</i> , "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," <i>Mol. Biol. Cell.</i> , 3:211-220 (February, 1992).
EA	C12	Betsholtz <i>et al.</i> , "cDNA Sequence and Chromosomal Localization of Human Platelet-Derived Growth Factor A-Chain and Its Expression in Tumor Cell Lines," <i>Nature</i> , 320:695-699 (April, 1986).
EA	C13	Borg <i>et al.</i> , "Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosine Kinase," <i>Oncogene</i> , 10:973-84 (1995).
EA	C14	Bowie <i>et al.</i> , "Deciphering the Message in Protein Sequences: tolerance to amino acid substitutions," <i>Science</i> , 247:1306-1310 (March 16, 1990).
EA	C15	Breier <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor During Embryonic Angiogenesis and Endothelial Cell Differentiation," <i>Development</i> , 114:521-532 (1992).
EA	C16	Cao <i>et al.</i> , "Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> , 271(6):3154-3162 (February 9, 1996).
EA	C17	Capecchi, M.R., "Altering the Genome by Homologous Recombination," <i>Science</i> , 244:1288-1292 (June 16, 1989)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1442 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

GA	C18	Chen and Shyu, "Selective Degradation of Early-Response-Gene mRNAs: Functional Analyses of Sequence Features of the AU-Rich Elements," <i>Mol. Cell Biol.</i> , 14(12):8471-8482 (December, 1994).
1	C19	Cheng and Flanagan, "Identification and Cloning of ELF-1, A Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases," <i>Cell</i> , 79:157-168 (October 7, 1994).
	C20	Claesson-Welsh <i>et al.</i> , "Identification and Structural Analysis of the A Type Receptor for Platelet-derived Growth Factor," <i>J. Biol. Chem.</i> , 264(3):1742-1747 (January 25, 1989).
	C21	Claesson-Welsh <i>et al.</i> , "cDNA Cloning and Expression of a Human Platelet-Derived Growth Factor (PDGF) Receptor Specific for B-Chain-Containing PDGF Molecules," <i>Mol. Cell Biol.</i> , 8(8):3476-3486 (August, 1988).
	C22	Claesson-Welsh <i>et al.</i> , "cDNA Cloning and Expression of the Human A-type Platelet-Derived Growth Factor (PDGF) Receptor Establishes Structural Similarity to the B-type PDGF Receptor," <i>Proc. Nat'l Acad. Sci., USA</i> , 86(13):4917-4921 (July, 1989).
	C23	Coffin <i>et al.</i> , "Angioblast Differentiation and Morphogenesis of the Vascular Endothelium in the Mouse Embryo," <i>Devel. Biol.</i> , 148:51-62 (1991).
	C24	Cohen, T. <i>et al.</i> , "VEGF <sub>121</sub> , A Vascular Endothelial Growth Factor (VEGF) Isoform Lacking Heparin Binding Ability, Requires Cell-Surface Heparan Sulfates for Efficient Binding to the VEGF Receptors of Human Melanoma Cells," <i>Journal of Biological Chemistry</i> , 270(19):11322-11326 (May 12, 1995).
	C25	Collins <i>et al.</i> , "Cultured Human Endothelial Cells Express Platelet-Derived Growth Factor B Chain: cDNA Cloning and Structural Analysis," <i>Nature</i> , 316:748-750 (August, 1985).
	C26	Cowling <i>et al.</i> , "Erythropoietin and Myeloid Colony Stimulating Factors," <i>TIBTECH</i> , 10(10):349-357 (October, 1992).
✓	C27	Curran and Franza, "Fos and Jun: The AP-1 Connection," <i>Cell</i> , 55:395-397 (November 4, 1988).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)  <b>INFORMATION DISCLOSURE STATEMENT</b>  <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. <b>28967/34140A</b>	Serial No. <b>09/534,376</b>
		Applicant <b>Alitalo <i>et al.</i></b>	
		Filing Date <b>March 24, 2000</b>	Group <b>1632</b>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
9A	C28	De Vries <i>et al.</i> , "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <i>Science</i> , 255:989-991 (February 21, 1992).
	C29	Dignam <i>et al.</i> , "Babiani Ring 3 in <i>Chironomus tentans</i> Encodes a 185-kDa Secretory Protein Which is Synthesized Throughout the Fourth Larval Instar," <i>Gene</i> , 88:133-140 (1990).
	C30	DiSalvo <i>et al.</i> , "Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor: Placenta Growth Factor Heterodimer," <i>J. Biol. Chem.</i> , 270(13):7717-7723 (March 31, 1995).
	C31	Don <i>et al.</i> , "'Touchdown' PCR to Circumvent Spurious Priming During Gene Amplification," <i>Nucl. Acids Res.</i> , 19: 4008 (1991).
	C32	Yonemura, Y., <i>et al.</i> , "Role of Vascular Endothelial Growth Factor C Expression in the Development of Lymph Node Metastasis in Gastric Cancer," <i>Clin. Cancer Res.</i> , 5:1823-1829 (July 1999).
	C33	Dumont <i>et al.</i> , "Dominant-negative and Targeted Null Mutations in the Endothelial Receptor Tyrosine Kinase, <i>tek</i> , Reveal a Critical Role in Vasculogenesis of the Embryo," <i>Genes Dev.</i> , 8:1897-1909 (1994).
	C34	Dumont <i>et al.</i> , "Vascularization of the Mouse Embryo: A Study of <i>flk-1</i> , <i>tek</i> , <i>tie</i> and Vascular Endothelial Growth Factor Expression During Development," <i>Development Dynamics</i> , 203:80-92 (1995).
	C35	Dvorak <i>et al.</i> , "Review: Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis," <i>Amer. J. Path.</i> , 146:1029-1039 (1995).
	C36	Eichmann <i>et al.</i> , "Two Molecules Related to the VEGF Receptor are Expressed in Early Endothelial Cells During Avian Embryonic Development," <i>Mech. Dev.</i> , 42:33-48 (1993).
	C37	Ferrara <i>et al.</i> , "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins," <i>Endocrine Rev.</i> , 13(1):18-32 (1992).
✓	C38	Finnerty <i>et al.</i> , "Molecular Cloning of Murine FLT and FLT4," <i>Oncogene</i> , 8(11):2293-2298 (1993).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 28967/34140A	Serial No. 09/534,376
	Applicant Alitalo <i>et al.</i>			
	Filing Date March 24, 2000	Group 1632		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
EPA	C39	Flamme <i>et al.</i> , "Vascular Endothelial Growth Factor (VEGF) and VEGF-Receptor 2 (flk-1) are Expressed During Vasculogenesis and Vascular Differentiation in the Quail Embryo," <i>Devel. Biol.</i> , 169:699-712 (1995).
	C40	Flanagan and Leder, "The <i>kit</i> Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," <i>Cell</i> , 63:185-194 (October 5, 1990).
	C41	Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," <i>Nature Med.</i> , 1(1):27-31 (1995).
	C42	Folkman <i>et al.</i> , "Angiogenesis," <i>J. Biol. Chem.</i> , 267(16):10931-10934 (June 5, 1992).
	C43	Folkman <i>et al.</i> , "Long-term Culture of Capillary Endothelial Cells," <i>Proc. Nat'l Acad. Sci., USA</i> , 76(10):5217-5221 (October, 1979).
	C44	Fong <i>et al.</i> , "Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium," <i>Nature</i> , 376:66-70 (July 6, 1995).
	C45	Fossum <i>et al.</i> , "Lymphedema Etiopathogenesis," <i>J. Vet. Int. Med.</i> , 6:283-293 (1992).
	C46	Fournier <i>et al.</i> , "Mutation of Tyrosine Residue 1337 Abrogates Ligand-Dependent Transforming Capacity of the FLT4 Receptor," <i>Oncogene</i> , 11(5):921-931 (September 7, 1995).
	C47	Friesel <i>et al.</i> , "Molecular Mechanisms of Angiogenesis: Fibroblast Growth Factor Signal Transduction," <i>FASEB J.</i> , 9:919-25 (1995).
	C48	Fukumura <i>et al.</i> , "Tumor Necrosis Factor $\alpha$ -induced Leukocyte Adhesion in Normal and Tumor Vessels: Effect of Tumor Type, Transplantation Site, and Host Strain," <i>Cancer Research</i> , 55:4824-4829 (November 1, 1995).
✓	C49	Galland <i>et al.</i> , "The <i>Flt4</i> Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," <i>Oncogene</i> , 8:1233-1240 (1993).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeApp. Docket No.  
28967/34140ASerial No.  
09/534,376**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
Alitalo *et al.*Filing Date  
March 24, 2000Group  
1632**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

ENA	C50	Genbank AA149461, "z127h03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 503189 5' similar to SW:BAR3_CHITE Q03376 BALBIANI RING PROTEIN 3 PRECURSOR," Deposited by Hillier, L. <i>et al.</i>
	C51	Genbank AA151613, "z127h03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 503189 3'," Hillier, L. <i>et al.</i> , Dated 14-May-1997
	C52	Genbank AA285997, "vb88h06.r1 Soares mouse 3NbMS Mus musculus cDNA clone 764123 5'," Deposited by Marra, M. <i>et al.</i>
	C53	Genbank, AA298182 "EST113866 Bone VII Homo sapiens cDNA 5' end," Deposited by Adams, M.D. <i>et al.</i> Dated 18-Apr-1997
	C54	Genbank AA298283, "EST113896 Bone VII Homo sapiens cDNA 5' end similar to similar to vascular endothelial growth factor," Deposited by Adams, M.D. <i>et al.</i> Dated 18-Apr-1997
	C55	Genbank AA406492, "zv12g06.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 75366 5'," Deposited by Hillier, L. <i>et al.</i> Dated 17-May-1997
	C56	Genbank AA421713, "zu24b03.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 738893 3'," Deposited by Hillier, L. <i>et al.</i> Dated 16-Oct-1997
	C57	Genbank AA425303, "zw46b06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773075 3', mRNA sequence," Deposited by Hillier, L. <i>et al.</i> Dated 16-Oct-1997
	C58	Genbank AA425486, "zw46b06.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773075 5' similar to SW:VEGF_MOUSE Q00731 VASCULAR ENDOTHELIAL GROWTH FACTOR PRECURSOR," Deposited by Hillier, L. <i>et al.</i>
	C59	Genbank AA478766, "zv18h12.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 754055 5'," Deposited by Hillier, L. <i>et al.</i> Dated 08-Aug-1997
	C60	Genbank AA479987, "zv18h12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 754055 3'," Deposited by Hillier, L. <i>et al.</i>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Any Docket No.

28967/34140A

Serial No.

09/534,376

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary.)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

EA	C61	Genbank AA549856, "0929m3 gmbPfHB3.1, G. Roman Reddy Plasmodium falciparum genomic clone 0929m," Deposited by Dame, J.B. <i>et al.</i> Dated 11-Aug-1997
	C62	Genbank C21512, "HUMGS0010510, Human Gene Signature, 3'-directed cDNA sequence," Deposited by Okubo, K. Dated 01-Oct-1996
	C63	Genbank H05134, "y185b08.s1 Homo sapiens cDNA clone 44993 3'," Deposited by Hillier, L. <i>et al.</i> Dated 21-Jun-1995
	C64	Genbank H05177, "y185b08.r1 Homo sapiens cDNA clone 44993 5'," Deposited by Hillier, L. <i>et al.</i> Dated 21-Jun-1995
	C65	Genbank H07899, "y186g06.s1 Homo sapiens cDNA clone 45138 3'," Deposited by Hillier, L. <i>et al.</i> Dated 23-Jun-1995
	C66	Genbank H81867, "yv83d09.r1 Homo sapiens cDNA clone 249329 5'," Deposited by Hillier, L. <i>et al.</i>
	C67	Genbank H81868, "yv83d09.s1 Homo sapiens cDNA clone 249329 3'," Deposited by Hillier, L. <i>et al.</i> Dated 09-Nov-1995
	C68	Genbank H96533, "yw04b12.r1 Soares melanocyte 2NbHM Homo sapiens cDNA clone 251231 5'," Deposited by Hillier, L. <i>et al.</i> Dated 25-Nov-1996
	C69	Genbank H96876, "yw04b12.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone 251231 3'," Deposited by Hillier, L. <i>et al.</i> Dated 25-Nov-1996
	C70	Genbank M21616, "Human Platelet-derived Growth Factor (PDGF) Receptor mRNA, Complete cds." Deposited by Claesson-Welsh <i>et al.</i> , Dated September 28, 1992.
	C71	Genbank M22734, "Human Platelet-derived Growth Factor A Type Receptor mRNA, Complete cds.," Deposited by Claesson-Welsh <i>et al.</i> , Dated January 7, 1995.
✓	C72	Genbank M32977, "Human Heparin-binding Vascular Endothelial Growth Factor (VEGF) mRNA, Complete cds." Deposited by Leung <i>et al.</i> , Dated February 28, 1991.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U. S. Department of Commerce Patent and Trademark Office	Atty. Docket No <b>28967/34140A</b>	Serial No <b>09/534,376</b>
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Applicant <b>Alitalo <i>et al.</i></b>	
		Filing Date <b>March 24, 2000</b>	Group <b>1632</b>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
GA	C73	Genbank N31713, "yy15b12.s1 Homo sapiens cDNA clone 271295 3'," Deposited by Hillier, L. <i>et al.</i> Dated 10-Jan-1996
1	C74	Genbank N31720, "yy15d12.s1 Homo sapiens cDNA clone 271319 3'," Deposited by Hillier, L. <i>et al.</i> Dated 10-Jan-1996
	C75	Genbank N42368, "yy15b11.r1 Homo sapiens cDNA clone 271293 5'," Deposited by Hillier, L. <i>et al.</i> Dated 25-Jan-1996
	C76	Genbank N42374, "yy15d11.r1 Homo sapiens cDNA clone 271317 5'," Deposited by Hillier, L. <i>et al.</i> Dated 25-Jan-1996
	C77	Genbank N50972, "yy94b08.s1 Homo sapiens cDNA clone 281175 3'," Deposited by Hillier, L. <i>et al.</i> Dated 14-Feb-1996
	C78	Genbank N82975, "TgESTzy53h10.r1 TgRH Tachyzoite cDNA Toxoplasma gondii cDNA clone tgzy53h10.r1 5'," Deposited by Hehl, A. <i>et al.</i> Dated 10-Sep-1997
	C79	Genbank N94399, "zb76f04.s1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 309535 3'," Deposited by Hillier, L. <i>et al.</i> Dated 20-Aug-1996
	C80	Genbank R77495, "yi79e04.s1 Homo sapiens cDNA clone 145470 3'," Deposited by Hillier, L. <i>et al.</i> Dated 07-Jun-1995
	C81	Genbank S66407, "FLT4 Receptor Tyrosine Kinase Isoform FLT4 Long (3' Region, Alternatively Spliced) [Human, mRNA Partial, 216 nt].." Deposited by Pajusola <i>et al.</i> , Dated December 17, 1993.
	C82	Genbank T81481, "yd29f07.s1 Homo sapiens cDNA clone 109669 3'," Deposited by Hillier, L. <i>et al.</i> Dated 15-Mar-1995
✓	C83	Genbank T81690, "yd29f07.r1 Homo sapiens cDNA clone 109669 5' similar to SP:BAR3_CHITE Q03376 BALBIANI RING PROTEIN 3," Deposited by Hillier, L. <i>et al.</i> Dated 15-Mar-1995

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

CA	C84	Genbank T84377, "yd37h08.r1 Homo sapiens cDNA clone 110463 5' similar to SP:BAR3_CHITE Q03376 BALBIANI RING PROTEIN 3," Deposited by Hillier, L. <i>et al.</i> Dated 16-Mar-1995
	C85	Genbank T89295, "yd37h08.s1 Homo sapiens cDNA clone 110463 3'," Deposited by Hillier, L. <i>et al.</i> Dated 20-Mar-1995
	C86	Genbank U48800, "Mus Musculus Vascular Endothelial Growth Factor B Precursor (VEGF-B) mRNA, Complete Cds.," Deposited by Olofsson <i>et al.</i> , Dated August 19, 1996.
	C87	Genbank U48801, "Human Vascular Endothelial Growth Factor B Precursor (VEGF-B) mRNA, Complete cds." Deposited by Olofsson <i>et al.</i> , Dated August 19, 1996.
	C88	Genbank X02811, "Human mRNA for Platelet-derived Growth Factor B Chain (PDGF-B)," Deposited by Collins <i>et al.</i> , Dated March 27, 1995.
	C89	Genbank X15997, "Human Vascular Permeability Factor mRNA, Complete Cds.," Deposited by Keck <i>et al.</i> , Dated June 15, 1990.
	C90	Genbank X54936, "H. sapiens mRNA for Placenta Growth Factor (PIGF)" Deposited by Persico, M.G., Dated November 12, 1991.
	C91	Genbank X60280, "Vector Plasmid pLTRpoly DNA.," Deposited by Maekela, T.P., Dated July 16, 1996.
	C92	Genbank X68203, "H. sapiens mRNA for FLT4, Class III Receptor Tyrosine Kinase.," Deposited by Aprelikova, O., Dated November 30, 1993.
	C93	Genbank X94216, "Homo sapiens mRNA for VEGF-C protein," Deposited by Joukov <i>et al.</i> , Dated February 6, 1996.
	C94	Genbank Z40230, "H. sapiens partial cDNA sequence; clone c-1wf11," Deposited by Genexpress. Dated 21-Sep-1995
✓	C95	Genbank Z44272, "H. sapiens partial cDNA sequence; clone c-1wf11," Deposited by Genexpress. Dated 21-Sep-1995

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

App. Docket No.

28967/34140A

Serial No.

09/534,376

**INFORMATION DISCLOSURE STATEMENT**

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

8A	C96	Harlow <i>et al.</i> , <i>Antibodies, a Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, pp. 72-137, 141-157, 287 & 321-358 (1988).
1	C97	Heldin <i>et al.</i> , "Structure of Platelet-Derived Growth Factor: Implications for Functional Properties," <i>Growth Factors</i> , 8:245-252 (1993).
	C98	Hillier <i>et al.</i> , "The WashU-Merck EST Project," EMBL Database entry HS991157. Accession No. H07991. July 2, 1995.
	C99	Hillier <i>et al.</i> , y185b08.21 Homo sapiens cDNA clone 44993 5'. EST-STS Accession No. H05177. 06/21/95
	C100	Hillier <i>et al.</i> , y186g06.r1 Homo sapiens cDNA clone 45138 5'. EST-STS Accession No. H07991 (June 23, 1995).
	C101	Hillier <i>et al.</i> , yd29f07.r1 Homo sapiens cDNA clone 109669 5' similar to SP:BAR3_CHITE Q03376 BALBIANI RING PROTEIN 3. EST-STS Accession No. T81690. 03/15/95
	C102	Jeltsch, M. <i>et al.</i> , "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," <i>Science</i> , 276:1423-1425 (May, 1997).
	C103	Joukov <i>et al.</i> , "A Novel Vascular Endothelial Growth Factor, VEGF-C, Is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," <i>EMBO J.</i> , 15(2):290-298 (1996).
	C104	Joukov, V. <i>et al.</i> , "A Novel Vascular Endothelial Growth Factor VEGF-C is A Ligand for the FLT4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," EMBL Sequence Data Library, XP002066362, accession no. X94216. Dated 01-Feb-1996
	C105	Joukov, V. <i>et al.</i> , "A Recombinant Mutant Vascular Endothelial Growth Factor-C that has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities," <i>Journal of Biological Chemistry</i> , 273(12):6599-6602 (March 20, 1998).
✓	C106	Joukov, V. <i>et al.</i> , "Proteolytic Processing Regulates Receptor Specificity and Activity of VEGF-C," <i>EMBO Journal</i> , 16(13):3898-3911 (June, 1997).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

App. Docket No.

28967/34140A

Serial No.

09/534.376

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

EA	C107	Kaipainen <i>et al.</i> , "Expression of the FMS-Like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," <i>Proc. Nat'l Acad. Sci., USA</i> , 92:3566-3570 (April, 1995).
	C108	Kaipainen <i>et al.</i> , "The Related FLT4, FLT1 and KDR Receptor Tyrosine Kinases Show Distinct Expression Patterns in Human Fetal Endothelial Cells," <i>J. Exp. Med.</i> , 178:2077-2088 (December, 1993).
	C109	Kaipainen <i>et al.</i> , "Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas," <i>Cancer Res.</i> , 54:6571-6577 (December 15, 1994).
	C110	Keyt <i>et al.</i> , "Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors," <i>J. Biol. Chem.</i> , 271(10):5638-5646 (March 8, 1996).
	C111	Kim <i>et al.</i> , "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies," <i>Growth Factors</i> , 7(1):53-64 (1992).
	C112	Korhonen <i>et al.</i> , "The Mouse Tie Receptor Tyrosine Kinase Gene: Expression During Embryonic Angiogenesis," <i>Oncogene</i> , 9:395-403 (1994).
	C113	Kozak, "An Analysis of 5'-Non-Coding Sequences from 699 Vertebrate Messenger RNAs," <i>Nucl. Acids Res.</i> 15: 8125-8148 (1987).
	C114	Kukk <i>et al.</i> , "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development," <i>Development</i> , 122:3829-3837 (1996).
	C115	Leak, L.V., "Electron Microscopic Observations on Lymphatic Capillaries and the Structural Components of the Connective Tissue-Lymph Interface," <i>Microvasc. Res.</i> , 2:361-391 (1970).
✓	C116	Lee <i>et al.</i> , "Vascular Endothelial Growth Factor-Related Protein: A Ligand and Specific Activator of the Tyrosine Kinase Receptor Flt4," <i>Proc. Nat'l Acad. Sci., USA</i> , 93:1988-1992 (March, 1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form: PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

EA	C117	Lee, J. <i>et al.</i> , "Vascular Endothelial Growth Factor Related Protein (vrp): A Ligand and Specific Activator of the Tyrosine Kinase Receptor Flt4," EMBL Sequence Data Library, XP002066361, accession no. U4142. Dated 10-Jan-1996
	C118	Leu <i>et al.</i> , "Flow Velocity in the Superficial Lymphatic Network of the Mouse Tail," <i>Am. J. Physiol.</i> , 267:H1507-H1513 (1994).
	C119	Leung <i>et al.</i> , "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <i>Science</i> , 246:1306-1309 (December 8, 1989).
	C120	Levy <i>et al.</i> , "Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia," <i>J. Biol. Chem.</i> , 271(5):2746-2753 (February 2, 1996).
	C121	Levy <i>et al.</i> , "Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia," <i>J. Biol. Chem.</i> , 270(22):13333-13340 (June 2, 1995).
	C122	Lyman <i>et al.</i> , "Molecular Cloning of a Ligand for the flt3/ftk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," <i>Cell</i> , 75:1157-1167 (December 17, 1993).
	C123	Maglione <i>et al.</i> , "Isolation of a Human Placenta cDNA Coding for a Protein Related to the Vascular Permeability Factor," <i>Proc. Nat'l Acad. Sci., USA</i> , 88:9267-9271 (October, 1991).
	C124	Maglione <i>et al.</i> , "Two Alternative mRNAs Coding for the Angiogenic Factor, Placenta Growth Factor (PlGF) are Transcribed from a Single Gene of Chromosome 14," <i>Oncogene</i> , 8:925-931 (1993).
	C125	Mäkelä <i>et al.</i> , "Plasmid pLTRpoly: A Versatile High-Efficiency Mammalian Expression Vector," <i>Gene</i> , 118: 293-294 (1992).
	C126	Matthews <i>et al.</i> , "A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit," <i>Proc. Nat'l Acad. Sci., USA</i> , 88:9026-9030 (October, 1991).
	C127	Metzelaar <i>et al.</i> , "CD63 Antigen," <i>J. of Biol. Chem.</i> , 266(5):3239-3245 (February 15, 1991).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

SA	C128	Miles <i>et al.</i> , "Vascular Reactions to Histamine, Histamine-Liberator and Leukotaxine in the Skin of Guinea-Pigs," <i>J. Physiol.</i> , 118:228-257 (1952).
	C129	Millauer <i>et al.</i> , "Glioblastoma Growth Inhibited <i>in vivo</i> by a Dominant-Negative Flk-1 Mutant," <i>Nature</i> , 367:576-579 (February 10, 1994).
	C130	Millauer <i>et al.</i> , "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <i>Cell</i> , 72:835-846 (March 26, 1993).
	C131	Mitchell <i>et al.</i> , "Transcription Factor AP-2 is Expressed in Neural Crest Cell Lineages During Mouse Embryogenesis," <i>Genes and Dev.</i> , 5:105-119 (1991).
	C132	Morgenstern <i>et al.</i> , "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors With Multiple Drug Selection Markers and a Complementary Helper-Free Packaging Cell Line," <i>Nucl. Acids Res.</i> , 18(12):3587-3595 (1990).
	C133	Mount, S.M., "A Catalogue of Splice Junction Sequences," <i>Nucl. Acids Res.</i> , 10(2):459-472 (1982).
	C134	Muragaki <i>et al.</i> , "Mouse <i>Coll8a1</i> is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones," <i>Proc. Nat'l Acad. Sci., USA</i> , 92:8763-8776 (September, 1995).
	C135	Mustonen <i>et al.</i> , "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biol.</i> , 129:895-898 (May, 1995).
	C136	Nelson and Sun, "The 50- and 58-kdalton Keratin Classes as Molecular Markers for Stratified Squamous Epithelia: Cell Culture Studies," <i>J. Cell Biol.</i> , 97:244-251 (July, 1983).
	C137	Neufeld, G. <i>et al.</i> , "Vascular Endothelial Growth Factor and Its Receptors," <i>Prog. Growth Fact. Res.</i> , 5:89-97 (1994).
	C138	Oefner <i>et al.</i> , "Crystal Structure of Human Platelet-derived Growth Factor BB," <i>EMBO J.</i> , 11(11):3921-3926 (1992).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeApp. Docket No.  
28967/34140ASerial No.  
09/534.376Applicant  
Alitalo *et al.*Filing Date  
March 24, 2000Group  
1632**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

EA	C139	Oelrichs <i>et al.</i> , "NYK/FLK-1: A Putative Receptor Tyrosine Kinase Isolated from E10 Embryonic Neuroepithelium is Expressed in Endothelial Cells of the Developing Embryo," <i>Oncogene</i> , 8:11-18 (1993).
	C140	Olofsson <i>et al.</i> , "Vascular Endothelial Growth Factor B, A Novel Growth Factor for Endothelial Cells," <i>Proc. Nat'l Acad. Sci., USA</i> , 93:2576-2581 (March, 1996).
	C141	Orlandini <i>et al.</i> , "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family," <i>Proc. Nat'l Acad. Sci., USA</i> , 93(21):11675-11680 (October, 1996).
	C142	Paavonen <i>et al.</i> , "Chromosomal Localization and Regulation of Human Vascular Endothelial Growth Factors B and C (VEGF-B and VEGF-C)," <i>IX International Vascular Biology Meeting</i> , Seattle, Washington, September 4-8, 1996, p. 76 (ABSTRACT 299).
	C143	Paavonen <i>et al.</i> , "Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively," <i>Circulation</i> 93(6):1079-1082 (March 15, 1996).
	C144	Pajusola, "Cloning and Characterization of a New Endothelial Receptor Tyrosine Kinase Flt4 and Two Novel VEGF-Like Growth Factors VEGF-B and VEGF-C," <i>Academic Dissertation, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute and Department of Biosciences, Division of Genetics, University of Helsinki</i> , (January 26, 1996)
	C145	Pajusola <i>et al.</i> , "FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin-Like Loops and Is Expressed in Multiple Human Tissues and Cell Lines," <i>Cancer Res.</i> , 52:5738-5743 (October 15, 1992).
	C146	Pajusola <i>et al.</i> , "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related to Two VEGF Receptors," <i>Oncogene</i> , 9:3545-3555 (1994).
	C147	Pajusola <i>et al.</i> , "Two Human FLT4 Receptor Tyrosine Kinase Isoforms With Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," <i>Oncogene</i> , 8: 2931-2937 (1993).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. <b>28967/34140A</b>	Serial No. <b>09/534,376</b>
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Applicant <b>Alitalo et al.</b>	
		Filing Date <b>March 24, 2000</b>	Group <b>1632</b>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
GA	C148	Park et al., "Placenta Growth Factor, Potentiation of Vascular Endothelial Growth Factor Bioactivity In vitro and In vivo, and High Affinity Binding to Flt-1 but not to Flk-1/KDR," <i>J. Biol. Chem.</i> , 269(41):25646-25654 (October 14, 1994).
	C149	Partanen et al., "A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains," <i>Mol. &amp; Cell. Biol.</i> , 12(4):1698-1707 (April, 1992).
	C150	Partanen et al., "Putative Tyrosine Kinases Expressed in K-562 Human Leukemia Cells," <i>Proc. Nat'l Acad. Sci., USA</i> , 87:8913-8917 (November, 1990).
	C151	Paulsson, G. et al., "The Balbiani Ring 3 Gene in <i>Chironomus tentans</i> has a Diverged Repetitive Structure Split by Many Introns," <i>J. Mol. Biol.</i> , 211:331-349 (1990).
	C152	Pear et al., "Production of High-titer Helper-free Retroviruses by Transient Transfection," <i>Proc. Nat'l Acad. Sci., USA</i> , 90:8392-8396 (September, 1993).
	C153	Pertovaara et al., "Vascular Endothelial Growth Factor Is Induced in Response to Transforming Growth Factor- $\beta$ in Fibroblastic and Epithelial Cells," <i>J. Biol. Chem.</i> , 269(9):6271-6274 (March 4, 1994).
	C154	Peters et al., "Vascular Endothelial Growth Factor Receptor Expression during Embryogenesis and Tissue Repair Suggests a Role in Endothelial Differentiation and Blood Vessel Growth," <i>Proc. Nat'l Acad. Sci., USA</i> , 90:8915-8918 (October, 1993).
	C155	Pötgens et al., "Covalent Dimerization of Vascular Permeability Factor/Vascular Endothelial Growth Factor Is Essential for Its Biological Activity," <i>J. Biol. Chem.</i> , 269(52):32879-32885 (December 30, 1994).
	C156	Pugh and Tijan, "Transcription from a TATA-less promoter requires a multisubunit TFIID complex," <i>Genes and Dev.</i> , 5:1935-1945 (1991)
✓	C157	Puri et al., "The Receptor Tyrosine Kinase TIE is Required for Integrity and Survival of Vascular Endothelial Cells," <i>EMBO J.</i> , 14:5884-5891 (1995).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

**INFORMATION DISCLOSURE STATEMENT**

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

EA	C158	Quinn <i>et al.</i> , "Fetal Liver Kinase 1 is a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," <i>Proc. Nat'l Acad. Sci., USA</i> , 90:7533-7537 (August, 1993).
	C159	Reeck <i>et al.</i> , "Homology" in proteins and nucleic acids: a terminology muddle and a way out of it [letter], <i>Cell</i> , 50:667 (August, 1987).
	C160	Risau <i>et al.</i> , "Changes on the Vascular Extracellular Matrix During Embryonic Vasculogenesis and Angiogenesis," <i>Devel. Biol.</i> , 125:441-450 (1988).
	C161	Risau <i>et al.</i> , "Platelet-Derived Growth Factor is Angiogenic <i>In Vivo</i> ," <i>Growth Factors</i> , 7:261-266 (1992).
	C162	Risau, W., "Differentiation of Endothelium," <i>FASEB J.</i> , 9:926-933 (1995).
	C163	Sabin, F.R., "The Lymphatic System in Human Embryos, With A Consideration of the Morphology of the System as a Whole," <i>Am. J. Anat.</i> , 9(1):43-91 (1909).
	C164	Saksela <i>et al.</i> , "Cell-Associated Plasminogen Activation: Regulation and Physiological Function," <i>Ann. Rev. Cell Biol.</i> , 4:93-126 (1988).
	C165	Sambrook <i>et al.</i> , <i>Molecular Cloning: a Laboratory Manual</i> , Second Edition, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1989), pp. 2.60-2.79, 4.21-4.32, 7.3-7.36, and 9.47-9.51.
	C166	Sato <i>et al.</i> , "Distinct Roles of the Receptor Tyrosine Kinases Tie-1 and Tie-2 in Blood Vessel Formation," <i>Nature</i> , 376:70-74 (July 6, 1995).
	C167	Schmelz <i>et al.</i> , "Complexus adhaerentes, A New Group of Desmoplakin-containing Junctions in Endothelial Cells: II. Different Types of Lymphatic Vessels," <i>Differentiation</i> , 57:97-117 (1994).
	C168	Schneider <i>et al.</i> , "A One-step Purification of Membrane Proteins Using a High Efficiency Immunomatrix," <i>J. Biol. Chem.</i> , 257(18):10766-70769 (September 25, 1982).
	C169	Seetharam <i>et al.</i> , "A Unique Signal Transduction from FLT Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor VEGF," <i>Oncogene</i> , 10:135-147 (1995).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Any. Docket No.

28967/34140A

Serial No.

09/534,376

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

EA	C170	Senger <i>et al.</i> , "Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid," <i>Science</i> , 219:983-985 (February 25, 1983).
	C171	Shalaby <i>et al.</i> , "Failure of Blood-Island Formation and Vasculogenesis in Flk-1-deficient Mice," <i>Nature</i> , 376:62-66 (July 6, 1995).
	C172	Shibuya <i>et al.</i> , "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene (flt) Closely Related to the fms Family," <i>Oncogene</i> , 5:519-524 (1990).
	C173	Shibuya, M., "Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis," <i>Adv. Cancer Res.</i> , 67:281-316 (1995).
	C174	Shweiki <i>et al.</i> , "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> , 91:2235-2243 (May, 1993).
	C175	Sitaras <i>et al.</i> , "Constitutive Production of Platelet-Derived Growth Factor-Like Proteins by Human Prostate Carcinoma Cell Lines," <i>Cancer Research</i> , 48(7):1930-1935 (April 1, 1988).
	C176	Southern and Berg, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," <i>J. Mol. Appl. Genet.</i> , 1:327-341 (1982).
	C177	Swartz <i>et al.</i> , "Transport in Lymphatic Capillaries. I. Macroscopic measurements using residence time distribution theory," <i>Am. J. Physiol.</i> , 270:H324-H329 (1996).
	C178	Terman <i>et al.</i> , "Identification of New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," <i>Oncogene</i> , 6:1677-1683 (1991).
	C179	Terman <i>et al.</i> , "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," <i>Biochem. Biophys. Res. Commun.</i> , 187:1579-1586 (September 30, 1992).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34140ASerial No.  
09/534,376**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
Alitalo *et al.*Filing Date  
March 24, 2000Group  
1632**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

ENA	C180	Terman <i>et al.</i> , "VEGF Receptor Subtypes KDR and FLT1 Show Different Sensitivities to Heparin and Placenta Growth Factor," <i>Growth Factors</i> , 11(3):187-195 (1994).
	C181	Tessier <i>et al.</i> , "Enhanced Secretion From Insect Cells of a Foreign Protein Fused to the Honeybee Melittin Signal Peptide," <i>Gene</i> , 98: 177-183 (1991).
	C182	Tischer <i>et al.</i> , "The Human Gene for Vascular Endothelial Growth Factor. Multiple Protein Forms are Encoded Through Alternative Exon Splicing," <i>J. Biol. Chem.</i> , 266(18):11947-11954 (June 25, 1991).
	C183	Udaka <i>et al.</i> , "Simple Method for Quantitation of Enhanced Vascular Permeability," <i>Proc. Soc. Exp. Biol. Med.</i> , 133:1384-1387 (1970).
	C184	Van der Geer <i>et al.</i> , "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," <i>Ann. Rev. Cell Biol.</i> , 10:251-337 (1994).
	C185	Vassar <i>et al.</i> , "Tissue-specific and Differentiation -specific Expression of a Human K14 Keratin Gene in Transgenic Mice," <i>Proc. Nat'l Acad. Sci., USA</i> , 86:1563-1567 (March, 1989).
	C186	Vassar <i>et al.</i> , "Transgenic Mice Provide New Insights Into the Role of TGF- $\alpha$ During Epidermal Development and Differentiation," <i>Genes &amp; Dev.</i> , 5:714-727 (1991).
	C187	Vassbotn <i>et al.</i> , "Reversion of Autocrine Transformation by a Dominant Negative Platelet-Derived Growth Factor Mutant," <i>Mol. Cell. Biol.</i> , 13(7):4066-4076 (July, 1993).
	C188	Västrik <i>et al.</i> , "Expression of the <i>Mad</i> Gene During Cell Differentiation <i>In Vivo</i> and Its Inhibition of Cell Growth <i>In Vitro</i> ," <i>J. Cell. Biol.</i> , 128(6):1197-1208 (March, 1995).
	C189	von Heijne, G., "A New Method for Predicting Signal Sequence Cleavage Sites," <i>Nucleic Acids Res.</i> , 14(11):4683-4690 (1986).
✓	C190	Waltenberger <i>et al.</i> , "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> , 269(43):26988-26995 (October 28, 1994).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U. S. Department of Commerce  
Patent and Trademark Office

App. Docket No.

28967/34140A

Serial No.

09/534,376

Applicant

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

EA	C191	Wanaka <i>et al.</i> , "Expression of FGF Receptor Gene in Rat Development," <i>Development</i> , 111:455-468 (1991).
f	C192	Witzenbichler, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>American Journal of Pathology</i> , Vol. 153, No.2:381-394 (August 1998).
	C193	Wen <i>et al.</i> , "Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," <i>Cell</i> 69:559-572 (May 1, 1992).
	C194	Yamane <i>et al.</i> , "A New Communication System Between Hepatocytes and Sinusoidal Endothelial Cells in Liver Through Vascular Endothelial Growth Factor and Flt Tyrosine Kinase Receptor Family (Flt-1 and KDR/Flk-1)," <i>Oncogene</i> , 9:2683-2690 (1994).
	C195	Hatva, E. <i>et al.</i> , "Vascular Growth Factors and Receptors in Capillary Hemangioblastomas and Hemangiopericytomas," <i>Am. J. Pathol.</i> , 148:763-775 (1996).
	C196	Böhling, T. <i>et al.</i> , "Expression of Growth Factors and Growth Factor Receptors in Capillary Hemangioblastoma," <i>J. Neuropathol. Exp. Neurol.</i> , 55:522-527 (1996).
	C197	Joukov <i>et al.</i> , "Identification of Csk Tyrosine Phosphorylation Sites and a Tyrosine Residue Important for Kinase Domain Structure," <i>Biochem. J.</i> , 322:927-935 (1997).
	C198	Enholm, B. <i>et al.</i> , "Comparison of VEGF, VEGF-B, VEGF-C, and Ang-1 mRNA Regulation by Serum, Growth Factors, Oncoproteins and Hypoxia," <i>Oncogene</i> , 14:2475-2483 (1997).
✓	C199	Oh, S.J. <i>et al.</i> , "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," <i>Dev. Biol.</i> , 188:96-109 (1997).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

Applicant:

Alitalo *et al.*

Filing Date

March 24, 2000

Group

1632

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

EA	C200	Chilov, D. et al., "Genomic Organization of Human and Mouse Genes for Vascular Endothelial Growth Factor C," <i>J. Biol. Chem.</i> , 272:25176-25183 (1997).
	C201	Cao, Y. et al., "Vascular Endothelial Growth Factor-C Induces Angiogenesis in Vivo," <i>Proc. Natl. Acad. Sci.</i> , 95:14389-14394 (1998).
	C202	Joukov, V. et al., "Vascular Endothelial Growth Factors VEGF-B and VEGF-C," <i>J. Cell. Physiol.</i> , 173:211-215 (1997).
	C203	Wang et al., "Signal Transduction in Human Hematopoietic Cells by Vascular Endothelial Growth Factor Related Protein, a Novel Ligand for the FLT4 Receptor," <i>Blood</i> , 90:3507-3515 (1997).
	C204	Alitalo, K., "Vascular Endothelial Growth Factors B and C and Receptors Involved in Angiogenesis," <i>IX International Vascular Biology Meeting</i> , Seattle, Washington, USA, September 4-8, 1996, p.1 (ABSTRACT).
	C205	Hu, J. et al., "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells," <i>FASEB J.</i> , 11:498-504 (1997).
	C206	GenBank Accession No. AAA85214 "Vascular Endothelial Growth Factor Related Protein," Deposited by Lee et al., dated January 9, 1996.
	C207	GenBank Accession No. U43142, "Human Vascular Endothelial Growth Factor Related Protein VRP mRNA," Deposited by Lee et al., dated January 9, 1996.
	C208	Fielder et al., "Expression of FLT4 and its Ligand VEGF-C in acute myeloid Leukemia," <i>Leukemia</i> , 11(8):1234-1237 (August, 1977).
	C209	Marchio, S., et al., "Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells," <i>J. Biol. Chem.</i> , 274(39):27617-22 (September 24, 1999).
	C210	Ohta, Y., et al., "VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours," <i>Br. J. Cancer</i> , 81(1):54-61 (September 1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Auy. Docket No.	Serial No
		28967/34140A	09/534.376
		Applicant	
		Alitalo <i>et al.</i>	
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Filing Date	Group
		March 24, 2000	1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
EPA	C211	Skobe, M., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi's Sarcoma," <i>J. Invest. Dermatology</i> , 113:1047-1053 (1999).
↓	C212	Tsurusaki, T., <i>et al.</i> , "Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis," <i>Br. J. Cancer</i> , 80(2):309-313 (1999).
✓	C213	Valtola, R., <i>et al.</i> , "VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer," <i>Am. J. Pathol.</i> , 154(5):1381-90 (May 1999).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	